Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alto NeuroscienceANRO +0.70%12 3-Year EBITDA Growth Rate is 0.40% as of Mar. 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,132 Biotechnology companies, Alto Neuroscience ranks worse than 68.55% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 0.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Alto Neuroscience was 0.40% per year. The lowest was -31.00% per year. And the median was -15.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Alto Neuroscience 3-Year EBITDA Growth Rate Related Terms
ANRO vs VOR, CGEM, OLMA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Alto Neuroscience's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alto Neuroscience 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alto Neuroscience's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Alto Neuroscience's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.40% mean?
Alto Neuroscience (ANRO) has a 3-Year EBITDA Growth Rate of 0.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alto Neuroscience and its competitors. According to the industry distribution chart, Alto Neuroscience ranks #776 out of 1132 companies in the Biotechnology industry, placing it in the top 68.6%.
Is Alto Neuroscience's 3-Year EBITDA Growth Rate too high?
Alto Neuroscience's current 3-Year EBITDA Growth Rate is 0.40%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Alto Neuroscience's value of 0.40% is 97.3% below this industry median. Based on the distribution chart, Alto Neuroscience ranks #776 out of 1132 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's 3-Year EBITDA Growth Rate compare to VOR and CGEM?
According to the Biotechnology industry distribution chart, Alto Neuroscience ranks #776 out of 1132 companies for 3-Year EBITDA Growth Rate. This places Alto Neuroscience in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Alto Neuroscience's value of 0.40% is 97.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,132 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alto Neuroscience's current 3-Year EBITDA Growth Rate of 0.40% is 97.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alto Neuroscience and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alto Neuroscience's current 3-Year EBITDA Growth Rate is 0.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current 3-Year EBITDA Growth Rate of 0.40%. The current 3-Year EBITDA Growth Rate is 0.40% and 97.3% below the Biotechnology industry median of 14.85. Alto Neuroscience's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current 3-Year EBITDA Growth Rate is 0.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score
Get the complete analysis for ANRO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANRO has been successfully added to your 
